HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Research Dictionary Pharma Mobile

Sign Up FREE or Login

SB 290157

Subscribe to New Research on SB 290157

an anaphylatoxin C3a receptor antagonist; structure in first source

Also Known As:

N2-((2,2-diphenylethoxy)acetyl)arginine; SB-290157; SB290157

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 58
- Hydrocarbons: 412
  - Cyclic Hydrocarbons: 3
    - Aromatic Hydrocarbons: 132
      - Benzene Derivatives: 13
        Benzhydryl Compounds
        SB 290157: 4
Amino Acids, Peptides, and Proteins
- Amino Acids: 10808

Experts

1.	Yoshino, Shin: 2 articles (01/2010 - 09/2009)
2.	Mizutani, Nobuaki: 2 articles (01/2010 - 09/2009)
3.	Ogawa, Naoki: 1 article (01/2010)
4.	Tsuga, Yuko: 1 article (01/2010)
5.	Takeda, Kohei: 1 article (01/2010)
6.	Tani, Mitsuhiro: 1 article (01/2010)
7.	Hutamekalin, Pilaiwanwadee: 1 article (01/2010)
8.	Nabe, Takeshi: 1 article (09/2009)
9.	Braun, Armin: 1 article (01/2005)
10.	Zwirner, Joerg: 1 article (01/2005)

Related Diseases

1.	Arthritis (Polyarthritis) 01/01/2010 - "The role of C3aRA in arthritis was investigated by injection of SB 290157 at concentrations of 10 and 30 mg/kg at 0 and 2 h. " 01/01/2010 - "Effect of the C3a-receptor antagonist SB 290157 on anti-OVA polyclonal antibody-induced arthritis." 05/15/2001 - "Furthermore, in animal models, SB 290157, inhibited neutrophil recruitment in a guinea pig LPS-induced airway neutrophilia model and decreased paw edema in a rat adjuvant-induced arthritis model. " 01/01/2010 - "It was investigated whether the C3a-receptor antagonist (C3aRA) SB 290157 was involved in the suppression of anti-OVA pAb-induced arthritis because it is well known that anaphylatoxin C3a plays a crucial role in the development of an effective inflammatory response during complement activation. "
2.	Leukemia 05/15/2001 - "The resulting antagonist, N(2)-[(2,2-diphenylethoxy)acetyl]-L-arginine (SB 290157), functioned as a competitive antagonist of (125)I-C3a radioligand binding to rat basophilic leukemia (RBL)-2H3 cells expressing the human C3aR (RBL-C3aR), with an IC(50) of 200 nM. SB 290157 was a functional antagonist, blocking C3a-induced C3aR internalization in a concentration-dependent manner and C3a-induced Ca(2+) mobilization in RBL-C3aR cells and human neutrophils with IC(50)s of 27.7 and 28 nM, respectively. "
3.	Hypersensitivity (Allergy) 01/15/2005 - "C3aR and C5a receptor (C5aR) signaling was blocked using the nonpeptidic C3aR antagonist SB290157 and the neutralizing C5aR mAb 20/70 in a murine model of Aspergillus fumigatus extract induced pulmonary allergy. "
4.	Edema 05/15/2001 - "Furthermore, in animal models, SB 290157, inhibited neutrophil recruitment in a guinea pig LPS-induced airway neutrophilia model and decreased paw edema in a rat adjuvant-induced arthritis model. "
5.	Airway Obstruction (Choking) 09/15/2009 - "On the other hand, SB290157 suppressed the increased expression of IL-1beta in the lung in this model, and the intratracheal administration of IL-1beta induced airway obstruction, airway hyperresponsiveness, and neutrophil infiltration in normal mice. "

Related Drugs and Biologics

1.	Arginine (L-Arginine)
2.	Anaphylatoxins
3.	complement C3a receptor